Evaluation of the safety of a coumarin-troxerutin combination

Pharmacoepidemiology and Drug Safety

Volumn 7, Issue SUPPL. 1, 1998, Pages

  Bruppacher, Rudolf ^a,c   Rieckemann, Bernd ^b   Naser Hijazi, Belal ^b   Wüstenberg, Peter ^b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b Schaper & Brummer GmbH & Co KG   (Germany)

^c NONE   (Switzerland)

Author keywords

Coumarins; Liver reactions; Safety assessment; Spontaneous reports

Indexed keywords

COUMARIN; TROXERUTIN;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG METABOLISM; DRUG SAFETY; FEMALE; GERMANY; HUMAN; JAUNDICE; LIVER TOXICITY; LYMPHEDEMA; MALE; PRIORITY JOURNAL; TOXIC HEPATITIS; VEIN DISEASE;

EID: 0031831374     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199808)7:1+3.0.CO;2-J     Document Type: Conference Paper

References (14)

1. Bartos, V. and Brzek, V. Die Wirkung von VENALOT® auf die Lymphströmung im Ductus thoracicus des Menschen. Medizinische Klinik 1970; 65: 1701-1703.
2. Köstering, H., Bandura, B., Merten, H. A. and Wieding, J. U. Das Verhalten der Blutgerinnung und deren Inhibitoren unter Langzeitbehandlung mit 5,6-Benzopyron (Cumarin). Arzneimittel-Forschung 1985; 35: 1303-1306.
3. Blume, J. and Wüstenberg, P. Chronische venöse-Insuffizienz (CVI): Behand-lungsergebnisse mit Benzopyronen bei und nach Kompressionstherapie. Therepiewoche 1996; 10: 540-544.
4. Beinssen, A. P. A. Possible coumarin hepatotoxicity. Medical Journal of Australia 1994; 161: 725.
5. Karch, F. E. and Lasagna, L. Adverse drug reactions/a critical review. Journal of the American Medical Association 1975; 234(12): 1236-1241.
6. Anonymous. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an International Consensus Meeting. International Journal of Clinical Pharmacology, Therapy and Toxicology 1990; 28(8): 317-322.
7. Faurschou, P. Toxic hepatitis due to Benzopyrone. Human Toxicology 1982; 1: 149-150.
8. Anonymous. Lebertoxische Wirkungen von Cumarin. Bundesgesundheitsblatt 1994; 3/94: 145-146.
9. Walker, A. and Cavanaugh, R. J. The occurrence of new hepatic disorders in defined population. Post Marketing Surveillance 1992; 6: 107-117.
10. Cox, D., O'Kennedy, R. and Thornes, R. D. The rarity of liver toxicity in patients treated with coumarin (1,2-Benzopyrone). Human Toxicology 1989; 8: 501-506.
11. Bassett, M. L. and Dahlstrom, J. E. Liver failure while taking coumarin. Medical Journal of Australia 1995; 163: 106.
12. Lake, B. G. and Grasso, P. Comparison of the hepatotoxicity of coumarin in the rat, mouse and syrian hamster: A dose and time response study. Fundamental and Applied Toxicology 1996; 34: 105-117.
13. 14C] coumarin by human liver microsomes. Xenobiotica 1994; 24: 795-803.
14. Evans, J. G., Gaunt, I. F. and Lake, B. G. Two-year toxicity study on coumarin in the baboon. Food and Cosmetics Toxicology 1979; 17: 187-193.